Cargando…

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia

Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor outcomes and relapse risk prediction approaches have not changed significantly in decades. To build a robust transcriptional risk prediction model for pediatric AML, we perform RNA-sequencing on 1503 primary diagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Benjamin J., Smith, Jenny L., Farrar, Jason E., Wang, Yi-Cheng, Umeda, Masayuki, Ries, Rhonda E., Leonti, Amanda R., Crowgey, Erin, Furlan, Scott N., Tarlock, Katherine, Armendariz, Marcos, Liu, Yanling, Shaw, Timothy I., Wei, Lisa, Gerbing, Robert B., Cooper, Todd M., Gamis, Alan S., Aplenc, Richard, Kolb, E. Anders, Rubnitz, Jeffrey, Ma, Jing, Klco, Jeffery M., Ma, Xiaotu, Alonzo, Todd A., Triche, Timothy, Meshinchi, Soheil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485122/ https://www.ncbi.nlm.nih.gov/pubmed/36123353 http://dx.doi.org/10.1038/s41467-022-33244-6

Ejemplares similares

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
por: Farrar, Jason E., et al.
Publicado: (2023)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

A B-cell developmental gene regulatory network is activated in infant AML
por: Bolouri, Hamid, et al.
Publicado: (2021)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
por: Bertrums, Eline J. M., et al.
Publicado: (2023)

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
por: Lim, Emilia L., et al.
Publicado: (2017)

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival
por: Pommert, Lauren, et al.
Publicado: (2022)

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Cytomolecular Organisation of the Nuclear Genome
por: Hasterok, Robert, et al.
Publicado: (2022)

Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group
por: Vujkovic, Marijana, et al.
Publicado: (2016)

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia
por: Narayanan, P., et al.
Publicado: (2021)

Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group
por: Kutny, Matthew A., et al.
Publicado: (2015)

Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
por: Getz, Kelly D., et al.
Publicado: (2016)

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019)

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017)

Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group
por: Li, Yimei, et al.
Publicado: (2015)

Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group
por: Johnston, Donna, et al.
Publicado: (2015)

Low cytomolecular diversification in the genus Stylosanthes Sw. (Papilionoideae, Leguminosae)
por: Franco, Ana Luiza, et al.
Publicado: (2020)

Cytomolecular characterization of de novo formed rye B chromosome variants
por: Marques, André, et al.
Publicado: (2012)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

The clinical and biological characteristics of NUP98-KDM5A pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2020)

The karyotype of Nothoscordum arenarium Herter (Gilliesioideae, Alliaceae): A populational and cytomolecular analysis
por: Souza, Luiz G. R., et al.
Publicado: (2009)

Cytomolecular Classification of Thyroid Nodules Using Fine-Needle Washes Aspiration Biopsies
por: Capitoli, Giulia, et al.
Publicado: (2022)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia
por: Umeda, Masayuki, et al.
Publicado: (2022)

Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication
por: Liu, Yanling, et al.
Publicado: (2023)

Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children’s Oncology Group report
por: Long, Xin, et al.
Publicado: (2017)

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling
por: Tarlock, Katherine, et al.
Publicado: (2018)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG
por: Rasche, Mareike, et al.
Publicado: (2021)

Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study
por: Ho, Phoenix A., et al.
Publicado: (2010)

Proposal of a new genomic framework for categorization of pediatric acute myeloid leukemia associated with prognosis
por: Umeda, Masayuki, et al.
Publicado: (2023)

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target
por: Le, Quy, et al.
Publicado: (2022)

Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia
por: Le, Quy, et al.
Publicado: (2023)

Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes
por: Bolouri, Hamid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l7qfl94pv9i5h3o3k6r6unass1